HER2 testing in gastric cancer: a practical approach View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-01-06

AUTHORS

Josef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale

ABSTRACT

Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro–esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro–esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab. More... »

PAGES

637-650

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/modpathol.2011.198

DOI

http://dx.doi.org/10.1038/modpathol.2011.198

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027273989

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22222640


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophageal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophagogastric Junction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Situ Hybridization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Silver Staining", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Pathology Nordhessen, Kassel, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Targos Molecular Pathology GmbH, Kassel, Germany", 
            "Institute of Pathology Nordhessen, Kassel, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "R\u00fcschoff", 
        "givenName": "Josef", 
        "id": "sg:person.0655033461.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655033461.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada", 
          "id": "http://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanna", 
        "givenName": "Wedad", 
        "id": "sg:person.0755325725.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755325725.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bilous", 
        "givenName": "Michael", 
        "id": "sg:person.01047412262.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047412262.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pathology Nordhessen, Kassel, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Institute of Pathology Nordhessen, Kassel, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hofmann", 
        "givenName": "Manfred", 
        "id": "sg:person.01346453747.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346453747.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415958.4", 
          "name": [
            "International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osamura", 
        "givenName": "Robert Y", 
        "id": "sg:person.01356461514.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356461514.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France", 
          "id": "http://www.grid.ac/institutes/grid.494717.8", 
          "name": [
            "Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Penault-Llorca", 
        "givenName": "Fr\u00e9d\u00e9rique", 
        "id": "sg:person.0643603315.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643603315.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.7177.6", 
          "name": [
            "Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van de Vijver", 
        "givenName": "Marc", 
        "id": "sg:person.01367247364.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367247364.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15667.33", 
          "name": [
            "Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Viale", 
        "givenName": "Giuseppe", 
        "id": "sg:person.012777104037.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012777104037.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00292-010-1278-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044174834", 
          "https://doi.org/10.1007/s00292-010-1278-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.3800774", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035152373", 
          "https://doi.org/10.1038/modpathol.3800774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10620-005-9057-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006218639", 
          "https://doi.org/10.1007/s10620-005-9057-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/01.mp.0000052102.90815.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043809974", 
          "https://doi.org/10.1097/01.mp.0000052102.90815.82"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10190-009-0037-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038032671", 
          "https://doi.org/10.1007/s10190-009-0037-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00428-010-0952-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008262506", 
          "https://doi.org/10.1007/s00428-010-0952-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-01-06", 
    "datePublishedReg": "2012-01-06", 
    "description": "Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro\u2013esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro\u2013esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/modpathol.2011.198", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1098208", 
        "issn": [
          "0893-3952", 
          "1530-0285"
        ], 
        "name": "Modern Pathology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "keywords": [
      "HER2 testing", 
      "European Medicines Agency", 
      "breast cancer", 
      "gastric cancer", 
      "Medicines Agency", 
      "gastro-esophageal junction cancer", 
      "human epidermal growth factor receptor 2", 
      "epidermal growth factor receptor 2", 
      "growth factor receptor 2", 
      "gastro-esophageal junction", 
      "treatment of patients", 
      "HER2 protein levels", 
      "Gastric Cancer Study", 
      "gastric cancer differs", 
      "factor receptor 2", 
      "incomplete membrane staining", 
      "trastuzumab use", 
      "metastatic adenocarcinoma", 
      "junction cancer", 
      "situ hybridization", 
      "immunohistochemistry 2", 
      "cancer differs", 
      "receptor 2", 
      "HER2 heterogeneity", 
      "predictive value", 
      "patients", 
      "recent approval", 
      "tumor biology", 
      "cancer", 
      "HER2", 
      "trastuzumab", 
      "heterogeneous staining", 
      "cancer studies", 
      "membrane staining", 
      "protein levels", 
      "expert pathologists", 
      "treatment", 
      "fluorescent methodologies", 
      "specific training", 
      "staining", 
      "testing protocol", 
      "approval", 
      "extensive experience", 
      "capecitabine", 
      "adenocarcinoma", 
      "gastric", 
      "testing", 
      "immunohistochemistry", 
      "stomach", 
      "cisplatin", 
      "pathologists", 
      "accurate identification", 
      "United States", 
      "recommendations", 
      "experience", 
      "inherent differences", 
      "indications", 
      "appropriate selection", 
      "scoring", 
      "hybridization", 
      "response", 
      "practical approach", 
      "practical guidance", 
      "levels", 
      "differences", 
      "study", 
      "protocol", 
      "training", 
      "panel", 
      "heterogeneity", 
      "guidance", 
      "junction", 
      "use", 
      "combination", 
      "differs", 
      "identification", 
      "samples", 
      "data", 
      "biology", 
      "countries", 
      "Japan", 
      "importance", 
      "agencies", 
      "values", 
      "testing methodology", 
      "fluorescence", 
      "selection", 
      "approach", 
      "state", 
      "methodology", 
      "silver", 
      "paper"
    ], 
    "name": "HER2 testing in gastric cancer: a practical approach", 
    "pagination": "637-650", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027273989"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/modpathol.2011.198"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22222640"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/modpathol.2011.198", 
      "https://app.dimensions.ai/details/publication/pub.1027273989"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_567.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/modpathol.2011.198"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2011.198'


 

This table displays all metadata directly associated to this object as RDF triples.

298 TRIPLES      22 PREDICATES      137 URIs      123 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/modpathol.2011.198 schema:about N0fbe641c81914dcaaac66f7b5ac927a2
2 N32b070343b524fedb59183f6c50bbdbf
3 N374aeedecbe34676995e42628cfc6853
4 N4d0d1eb0bcdf43e282991dd8f2a859e5
5 N6191385b4b25453ea590095a725379bf
6 N7a357ce937b64c44a2d388e873d67938
7 N8e1845aaf0af49ecae3afd88d3fa90f9
8 N8e80479a12204afd852b92d98253d183
9 Nb3abb77d2cfb4584822c52d5948f7b6f
10 Nc549791578e54a789f6e7a30305ca425
11 Ncd716740dcdc486aac8e3d3afaeaeb4e
12 Nd2f636a6f8194b8681f33bdd6309bf01
13 Nd5e4ceb19a6e4b4a8e7254d303c7793b
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N3ec4f6d861fe45c0a9c08dec5d231a12
17 schema:citation sg:pub.10.1007/s00292-010-1278-1
18 sg:pub.10.1007/s00428-010-0952-2
19 sg:pub.10.1007/s10190-009-0037-8
20 sg:pub.10.1007/s10620-005-9057-1
21 sg:pub.10.1038/modpathol.3800774
22 sg:pub.10.1097/01.mp.0000052102.90815.82
23 schema:datePublished 2012-01-06
24 schema:datePublishedReg 2012-01-06
25 schema:description Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro–esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2 testing and scoring to ensure accurate identification of patients eligible for treatment. HER2 testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2 heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2 testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2 protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2 testing in gastric cancer, irrespective of the experience of HER2 testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2 testing and scoring in patients with gastric and gastro–esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2 testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2 testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf Na904cd2152f14c9da7e651ac225a4c1c
30 Nb34f86456398450ea96b40f9569d89da
31 sg:journal.1098208
32 schema:keywords European Medicines Agency
33 Gastric Cancer Study
34 HER2
35 HER2 heterogeneity
36 HER2 protein levels
37 HER2 testing
38 Japan
39 Medicines Agency
40 United States
41 accurate identification
42 adenocarcinoma
43 agencies
44 approach
45 appropriate selection
46 approval
47 biology
48 breast cancer
49 cancer
50 cancer differs
51 cancer studies
52 capecitabine
53 cisplatin
54 combination
55 countries
56 data
57 differences
58 differs
59 epidermal growth factor receptor 2
60 experience
61 expert pathologists
62 extensive experience
63 factor receptor 2
64 fluorescence
65 fluorescent methodologies
66 gastric
67 gastric cancer
68 gastric cancer differs
69 gastro-esophageal junction
70 gastro-esophageal junction cancer
71 growth factor receptor 2
72 guidance
73 heterogeneity
74 heterogeneous staining
75 human epidermal growth factor receptor 2
76 hybridization
77 identification
78 immunohistochemistry
79 immunohistochemistry 2
80 importance
81 incomplete membrane staining
82 indications
83 inherent differences
84 junction
85 junction cancer
86 levels
87 membrane staining
88 metastatic adenocarcinoma
89 methodology
90 panel
91 paper
92 pathologists
93 patients
94 practical approach
95 practical guidance
96 predictive value
97 protein levels
98 protocol
99 recent approval
100 receptor 2
101 recommendations
102 response
103 samples
104 scoring
105 selection
106 silver
107 situ hybridization
108 specific training
109 staining
110 state
111 stomach
112 study
113 testing
114 testing methodology
115 testing protocol
116 training
117 trastuzumab
118 trastuzumab use
119 treatment
120 treatment of patients
121 tumor biology
122 use
123 values
124 schema:name HER2 testing in gastric cancer: a practical approach
125 schema:pagination 637-650
126 schema:productId N37684f6271604111a024fed8f02717eb
127 N985be9a36286489095b6fbf16298053c
128 Nbe3e24bb7aac4cf29d7b8603e067504a
129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027273989
130 https://doi.org/10.1038/modpathol.2011.198
131 schema:sdDatePublished 2022-05-20T07:28
132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
133 schema:sdPublisher N64402abfdb8442fc9b5b6aa9aaa0dbdc
134 schema:url https://doi.org/10.1038/modpathol.2011.198
135 sgo:license sg:explorer/license/
136 sgo:sdDataset articles
137 rdf:type schema:ScholarlyArticle
138 N04dc2118ce0648c8835b26a18769d3af rdf:first sg:person.01367247364.80
139 rdf:rest N733c871ddb824f69afeafa3da5603d80
140 N0fbe641c81914dcaaac66f7b5ac927a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Silver Staining
142 rdf:type schema:DefinedTerm
143 N28f2b2abb83a4e5089761e44a10133c9 rdf:first sg:person.0643603315.57
144 rdf:rest N04dc2118ce0648c8835b26a18769d3af
145 N32b070343b524fedb59183f6c50bbdbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Practice Guidelines as Topic
147 rdf:type schema:DefinedTerm
148 N374aeedecbe34676995e42628cfc6853 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Stomach Neoplasms
150 rdf:type schema:DefinedTerm
151 N37684f6271604111a024fed8f02717eb schema:name doi
152 schema:value 10.1038/modpathol.2011.198
153 rdf:type schema:PropertyValue
154 N3ec4f6d861fe45c0a9c08dec5d231a12 rdf:first sg:person.0655033461.67
155 rdf:rest Na578c77cfc9f458c8c4268ab9ca5e5c6
156 N4d0d1eb0bcdf43e282991dd8f2a859e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Immunohistochemistry
158 rdf:type schema:DefinedTerm
159 N6191385b4b25453ea590095a725379bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Trastuzumab
161 rdf:type schema:DefinedTerm
162 N64402abfdb8442fc9b5b6aa9aaa0dbdc schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 N733c871ddb824f69afeafa3da5603d80 rdf:first sg:person.012777104037.00
165 rdf:rest rdf:nil
166 N7a357ce937b64c44a2d388e873d67938 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Humans
168 rdf:type schema:DefinedTerm
169 N8e1845aaf0af49ecae3afd88d3fa90f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Receptor, ErbB-2
171 rdf:type schema:DefinedTerm
172 N8e80479a12204afd852b92d98253d183 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name In Situ Hybridization
174 rdf:type schema:DefinedTerm
175 N985be9a36286489095b6fbf16298053c schema:name pubmed_id
176 schema:value 22222640
177 rdf:type schema:PropertyValue
178 Na578c77cfc9f458c8c4268ab9ca5e5c6 rdf:first sg:person.0755325725.02
179 rdf:rest Naab618078edb49febc53528c3ef833a2
180 Na904cd2152f14c9da7e651ac225a4c1c schema:issueNumber 5
181 rdf:type schema:PublicationIssue
182 Naab618078edb49febc53528c3ef833a2 rdf:first sg:person.01047412262.17
183 rdf:rest Nd4190a44e70443a09a3b0185e1154cc3
184 Nb34f86456398450ea96b40f9569d89da schema:volumeNumber 25
185 rdf:type schema:PublicationVolume
186 Nb3abb77d2cfb4584822c52d5948f7b6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Esophagogastric Junction
188 rdf:type schema:DefinedTerm
189 Nbe3e24bb7aac4cf29d7b8603e067504a schema:name dimensions_id
190 schema:value pub.1027273989
191 rdf:type schema:PropertyValue
192 Nc549791578e54a789f6e7a30305ca425 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Antibodies, Monoclonal, Humanized
194 rdf:type schema:DefinedTerm
195 Ncd716740dcdc486aac8e3d3afaeaeb4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Antineoplastic Agents
197 rdf:type schema:DefinedTerm
198 Nd2f636a6f8194b8681f33bdd6309bf01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Esophageal Neoplasms
200 rdf:type schema:DefinedTerm
201 Nd4190a44e70443a09a3b0185e1154cc3 rdf:first sg:person.01346453747.06
202 rdf:rest Ne529620631d6409b8a921c1bf71b7b45
203 Nd5e4ceb19a6e4b4a8e7254d303c7793b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Adenocarcinoma
205 rdf:type schema:DefinedTerm
206 Ne529620631d6409b8a921c1bf71b7b45 rdf:first sg:person.01356461514.40
207 rdf:rest N28f2b2abb83a4e5089761e44a10133c9
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
212 schema:name Oncology and Carcinogenesis
213 rdf:type schema:DefinedTerm
214 sg:journal.1098208 schema:issn 0893-3952
215 1530-0285
216 schema:name Modern Pathology
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.01047412262.17 schema:affiliation grid-institutes:grid.1013.3
220 schema:familyName Bilous
221 schema:givenName Michael
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047412262.17
223 rdf:type schema:Person
224 sg:person.012777104037.00 schema:affiliation grid-institutes:grid.15667.33
225 schema:familyName Viale
226 schema:givenName Giuseppe
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012777104037.00
228 rdf:type schema:Person
229 sg:person.01346453747.06 schema:affiliation grid-institutes:None
230 schema:familyName Hofmann
231 schema:givenName Manfred
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346453747.06
233 rdf:type schema:Person
234 sg:person.01356461514.40 schema:affiliation grid-institutes:grid.415958.4
235 schema:familyName Osamura
236 schema:givenName Robert Y
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356461514.40
238 rdf:type schema:Person
239 sg:person.01367247364.80 schema:affiliation grid-institutes:grid.7177.6
240 schema:familyName van de Vijver
241 schema:givenName Marc
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367247364.80
243 rdf:type schema:Person
244 sg:person.0643603315.57 schema:affiliation grid-institutes:grid.494717.8
245 schema:familyName Penault-Llorca
246 schema:givenName Frédérique
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643603315.57
248 rdf:type schema:Person
249 sg:person.0655033461.67 schema:affiliation grid-institutes:None
250 schema:familyName Rüschoff
251 schema:givenName Josef
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655033461.67
253 rdf:type schema:Person
254 sg:person.0755325725.02 schema:affiliation grid-institutes:grid.413104.3
255 schema:familyName Hanna
256 schema:givenName Wedad
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755325725.02
258 rdf:type schema:Person
259 sg:pub.10.1007/s00292-010-1278-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044174834
260 https://doi.org/10.1007/s00292-010-1278-1
261 rdf:type schema:CreativeWork
262 sg:pub.10.1007/s00428-010-0952-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008262506
263 https://doi.org/10.1007/s00428-010-0952-2
264 rdf:type schema:CreativeWork
265 sg:pub.10.1007/s10190-009-0037-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038032671
266 https://doi.org/10.1007/s10190-009-0037-8
267 rdf:type schema:CreativeWork
268 sg:pub.10.1007/s10620-005-9057-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006218639
269 https://doi.org/10.1007/s10620-005-9057-1
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/modpathol.3800774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035152373
272 https://doi.org/10.1038/modpathol.3800774
273 rdf:type schema:CreativeWork
274 sg:pub.10.1097/01.mp.0000052102.90815.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043809974
275 https://doi.org/10.1097/01.mp.0000052102.90815.82
276 rdf:type schema:CreativeWork
277 grid-institutes:None schema:alternateName Institute of Pathology Nordhessen, Kassel, Germany
278 schema:name Institute of Pathology Nordhessen, Kassel, Germany
279 Targos Molecular Pathology GmbH, Kassel, Germany
280 rdf:type schema:Organization
281 grid-institutes:grid.1013.3 schema:alternateName Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia
282 schema:name Healthscope Pathology, Norwest Private Hospital, Faculty of Medicine University of Sydney, Sydney, Australia
283 rdf:type schema:Organization
284 grid-institutes:grid.15667.33 schema:alternateName Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy
285 schema:name Department of Pathology and Laboratory Medicine, University of Milan and European Institute of Oncology, Milan, Italy
286 rdf:type schema:Organization
287 grid-institutes:grid.413104.3 schema:alternateName Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada
288 schema:name Department of Laboratory Medicine and Pathobiology, Anatomic Pathology, Sunnybrook Health Sciences Center, Faculty of Medicine, University of Toronto, Toronto, Canada
289 rdf:type schema:Organization
290 grid-institutes:grid.415958.4 schema:alternateName International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan
291 schema:name International University of Health and Welfare (IUHW), Center for Diagnostic Pathology, IUHW Mita Hospital, Tokyo, Japan
292 rdf:type schema:Organization
293 grid-institutes:grid.494717.8 schema:alternateName Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France
294 schema:name Department of Pathology, Centre Jean Perrin and University of Auvergne, Clermont-Ferrand, France
295 rdf:type schema:Organization
296 grid-institutes:grid.7177.6 schema:alternateName Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands
297 schema:name Department of Pathology, The Academic Medical Center (AMC), The University of Amsterdam, Amsterdam, The Netherlands
298 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...